Influenza virus characterisation: Summary Europe, September to December 2012
The latest issue of ECDC’s monthly series on 'Influenza virus characterisation’ covers the time period from September to December 2012.
Since 1 September 2012, A(H1N1)pdm09, A(H3N2) and B/Victoria and B/Yamagata lineage influenza viruses have been detected in relatively low numbers in ECDC-affiliated countries.
The latest issue of ECDC’s monthly series on 'Influenza virus characterisation’ covers the time period from September to December 2012. It is a follow-up of the previous month's report.
Since 1 September 2012, A(H1N1)pdm09, A(H3N2) and B/Victoria and B/Yamagata lineage influenza viruses have been detected in relatively low numbers in ECDC-affiliated countries. The report summarises the findings as follows:
Type A and type B viruses are co-circulating in approximately equal proportions.
A(H3N2) and A(H1N1)pdm09 viruses have been detected at comparable levels, with a recent rise in the proportion of A(H1N1)pdm09 viruses.
A(H1N1)pdm09 viruses continued to show genetic drift from the vaccine virus, A/California/07/2009, but the vast majority remained antigenically similar to it.
The vast majority of A(H3N2) viruses have been antigenically similar to A/Victoria/361/2011, the vaccine virus for the 2012–13 influenza season.
B/Victoria lineage viruses fell within, and were antigenically similar to, reference cell-propagated viruses of the B/Brisbane/60/2008 genetic clade.
Recent B/Yamagata-lineage viruses fell into two genetic clades: clade 2 represented by B/Estonia/55669/2012, and clade 3 represented by B/Wisconsin/1/2010 (the vaccine component for the 2012–13 influenza season). Clade 2 viruses have predominated over clade 3.
The next influenza virus characterisation report will be published in March 2013 and will cover data on the 2012-2013 influenza season from September 2012 to February 2013.
For further details, download the complete report 'Influenza virus characterisation - Summary Europe, December 2012'.
Expert panel reviews neuraminidase inhibitors for the prevention and treatment of influenza
An ECDC expert opinion concludes that there is clear evidence supporting the use of neuraminidase inhibitors in the treatment and prevention of influenza. Moreover, the current recommendations in European countries on the use of the neuraminidase inhibitors oseltamivir and zanamivir are appropriate and should be applied by prescribing physicians.Read more
Epidemiological update: Review of influenza season 2016–2017 in the EU/EEA
The influenza season 2016–2017 has now come to an end in Europe. In week 17/2017, all EU/EEA countries reported low influenza activity and the positivity rate (proportion of influenza virus positives among all tested specimens) falling below the 10% benchmark to 9.9%. For the previous six weeks, almost all EU/EEA countries had reported low influenza activity.Read more